Eden Biltibo, MD
Hematology & Oncology · Nashville, TNNPI 1104244458
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.5%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Pfizer at 53.5% of the total. 2025 is the largest year on record at $2,936, more than ten times the $46 reported in 2020. That places this record below the midpoint for hematology & oncology clinicians in TN, where the typical reported total is $5,575.
Across 11 payments — averaging $462.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$3K
- Beigene USA, Inc.$2K
- Johnson & Johnson$184
- Janssen Scientific Affairs, LLC$150
- Gilead$32
- Amgen$17
- plus $29 from 2 others
What the payments were for
- Consulting fees$2,82055%
- Speaking & faculty fees$2,00039%
- Food & beverage$2625%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 3 | $2,720 |
| Beigene USA, Inc. | 1 | $1,950 |
| Johnson & Johnson | 2 | $184 |
| Janssen Scientific Affairs, LLC | 1 | $150 |
| Gilead | 1 | $32 |
| Amgen | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,082 in reported general payments places this provider in the 45th percentile of 251 hematology & oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 12 | $239,848 |
| ValacyclovirValacyclovir Hcl | 19 | $1,089 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Nashville
- Jonathan AbbasNashville$1.3M
- Alan TanNashville$1.1M
- Kent ShihNashville$900K
- Brian RiniNashville$601K
- Wade IamsNashville$601K
- Krish PatelNashville$531K
- Sandeep RajanNashville$465K
- Todd BauerNashville$357K
- Muhamed BaljevicNashville$313K
- Olalekan OluwoleNashville$311K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.